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Abstract 
 
A tumor often consists of multiple cell subpopulations (clones). Current chemo-
treatments often target one clone of a tumor. Although the drug kills that clone, other 
clones overtake it and the tumor reoccurs. Genome sequencing and computational 
analysis allows to computational dissection of clones from tumors, while singe-cell 
genome sequencing including RNA-Seq allows to profiling of these clones. This opens a 
new window for treating a tumor as a system in which clones are evolving. Future cancer 
systems biology studies should consider a tumor as an evolving system with multiple 
clones. Therefore, topics discussed in Part 2 of this review include evolutionary dynamics 
of clonal networks, early-warning signals (e.g., genome duplication events) for formation 
of fast-growing clones, dissecting tumor heterogeneity, and modeling of clone-clone-
stroma interactions for drug resistance. The ultimate goal of the future systems biology 
analysis is to obtain a ‘whole-system’ understanding of a tumor and therefore provides a 
more efficient and personalized management strategies for cancer patients.  
 
Keywords: 
Genome sequencing, systems biology, signaling network, cancer evolution, tumor 
heterogeneity, tumor clone, drug resistance, early-warning signal, personalized medicine 
 
 
 
 3 
 
1. Introduction  
 
The transformation from a normal cell into a tumor cell is a gradual evolution process in 
which genomic alterations accumulate in a step-wise manner. We described several 
models of tumorigenesis in Part 1 of this review [1]. These models suggest that for most 
of the tumors, tumorigenesis involves progression from early, slow-growing clones to 
late, fast-growing clones [1]. Although clones within a tumor are genetically related, they 
gain different growth or invasive capabilities so that they may have different response to 
a drug treatment.          
 
In the past decade, cancer systems biology research has led to a series of discoveries and 
the development of new methods [2,3]. For example, network approaches have led to 
identification of high-quality cancer prognostic biomarkers [4-6] and drug target 
discovery and drug repositioning [7,8]; Network modeling of network modules and 
motifs has not only pinpointed biomarkers, but also provided insights into cancer 
therapies [9-18]. For example, analysis of signaling networks with cancer mutation 
[19,20] and cancer phosphoproteomic data [21] suggests that cancer signaling is highly 
enriched in the network regions which are defined by the hub kinases and hub kinase 
substrates. In addition, a series of methods for reverse-engineering of gene regulatory 
networks have been developed [22,23]. However, almost all of these studies have focused 
on different types of omic data derived from whole tumors. These data represent readouts 
of mixed clones from the tumors, and therefore, introduce lots of noise and make the 
network modeling inaccurate.  
 
Advances in genome sequencing technology allows for computational dissection of 
clones and reconstruction of the evolutionary history of the tumors [1,24,25]. Emerging 
single-cell genome sequencing and RNA-Seq technologies allows to obtaining genomic 
alterations and gene expression profiles for individual clones. By accessing the omic data 
at the clone level, we could conduct systems biology studies of tumor clones. In Part 1 [1] 
of this review, we described the computational quantification of tumor subpopulations; 
clone-based network modeling, cancer hallmark-based networks and their high-order 
rewiring principles and the principles of cell survival networks of fast-growing clones. 
For example, network modeling (Zaman et al. unpublished observations) of cancer fast-
growing clones uncovered the principles of the cancer cell survival signaling networks – 
a set of genes are recurrently used by genomic alterations (mutations and copy number 
variations) and cancer essential genes (i.e., knocking-down such a gene leads to cancer 
cell death). Theses cancer cell survival networks represent an end-point of cancer cell 
survival signaling machine. It would be interesting to know how genomic alterations 
drive cancer cells to converge to the cancer survival networks, what the differences are 
between the networks of the clones within a tumor, and how to treat a cancer patient and 
overcome drug resistance by managing the patient’s tumor clones.   
 
To answer these questions, it is necessary to model the evolutionary dynamics of clonal 
networks, clone-clone and clone-stroma interactions to understand how a tumor is 
evolving and how drug resistance emerges. Therefore, in Part 2 of this review we will 
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discuss clonal network evolution, sharp transition warning signals from slow-growing to 
fast-growing clones, and how drug resistance could result from clonal backup and clone-
stroma interactions. Understanding of these issues from a systems biology point of view 
will help in understanding of a tumor as ‘a whole system’ and finally in developing 
personalized strategies to manage cancer patients.   
 
2. Evolutionary dynamics of clonal networks and early-warning signals of fast-
growing clone formation  
Tumorigenesis is typically viewed as a gradual evolution process, taking years to 
accumulate the multiple genomic alterations required to drive the cancer's aggressive 
growth. Genome sequencing of breast cancer and leukemia [24,26] suggests that 
mutational processes evolve across the lifespan of a tumor. As the cells accumulate many 
thousands of mutations, the developing cancer starts to diverge into clones of genetically 
related cells. By the time the cancer is diagnosed in a clinical setting, one of these clones 
has become the dominant population in the tumor, so that the tumor is clinically 
‘detectable’ to doctors. These studies suggest that evolution holds the key to 
understanding why tumors often recur after treatment, and to the development of better 
therapies. 
With new computational tools [27,28], we could dissect the mutations in the contexts of 
timing and clones. These data open a new opportunity to model the evolutionary 
dynamics of molecular networks of the clones within a tumor. The mutation and copy 
number variations (CNV) data could be used to construct clone-based cell survival 
networks. By modeling of the rewiring of these networks along the timing of clonal 
development, we could understand how and why these clones evolved and even predict 
new mutations based on a given clonal network. Previously, without using clonal 
information, a dynamic cascaded method (DCM), which is based on the intra-stage 
steady-rate assumption and the continuity assumption, has been used to reconstruct 
dynamic gene networks from sample-based transcriptional data for evolving networks 
[29]. Similar approaches could be applied to tumor clones. In addition, by taking into 
account the default genetic profiles of cell of origins, germline variants (e.g., derived 
from GWAS, genome-wide association studies), and system-constraints (see Part 1 of 
this review [1]), it is possible to infer specific combinatory patterns of genomic 
alterations in networks. By doing so, we could identify recurrent network modules which 
represent preferred clonal evolutionary paths. Different clonal evolutionary paths can be 
translated into predictions for predisposition and drug intervention.  
 
The process of cancer initiation and progression is a natural experimental evolutionary 
system. The evolutionary process of cancer cells is highly dynamic. In general, a wide 
range of complex systems including physics, physiology, ecology and social sciences 
have critical transitions. It is becoming increasingly clear that many complex systems 
have critical thresholds, so-called tipping points, at which the system shifts abruptly from 
one state to another [30]. For cancer cells, the surprising shift that occurs during the 
cancer cell evolution is marked by the sharply different states between a fast-growing 
clone and its direct mother clone. Evolutionary studies via genome sequencing suggest 
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that fast-growing clones come late and are derived from slow-growing clones of the early 
stage in tumorigenesis. Previous studies suggest that mutations in cancer cell evolution 
play an additive/accumulative role in a small-scale and gradual manner [31]. However, 
based on evolutionary studies via genome sequencing, we expect that certain genomic 
alterations drive a sharp transition between a fast-growing clone and its direct mother (a 
slow-growing clone). In this regard, it is interesting to model and compare clonal 
networks, especially between fast-growing clone and its direct mother. Such a study 
could reveal early-warning signals for forming fast-growing clones. In the past, most 
network evolution studies have focused on single networks or comparisons of networks 
of different species [21,32-34]. For tumor clonal evolution, we could focus on time-
course networks (i.e., networks reflect the time series of clonal evolution within a tumor).  
 
Without the expansion of a fast-growing clone, a tumor can’t be formed. If we could 
detect the early-warning signals for the sharp transition, cancer prevention strategies 
could be applied at this stage [35,36]. Theoretically, highly complex systems such as 
ecosystems have shown expected early-warning signals [30]. Sharp transitions are related 
to ‘catastrophic bifurcations’, where, once a threshold is exceeded, a positive feedback 
pushes the system through a phase of directional change towards a contrasting state [30]. 
Capturing the essence of shifts at tipping points in cell signaling pathways has been 
attempted [37]. To model cancer clonal evolution and identify potential early-warning 
signals, the networks should reflect the relations of genomic alterations and cell 
proliferation functions – cell proliferation, cell cycle, and apoptosis. Some positive 
regulatory loops or positive network feedback motifs could encode the early-warning 
signals. Positive feedback is widely observed in complex systems, ranging from cellular 
circuits to ecosystems. A handful of evidence has shown that positive feedback leads to 
alternative stable states and tipping points in various ecological systems. Furthermore, 
such loops might be organized into a set of bi-stable or multi-stable circuits exhibiting 
switch-like behavior. Bistable switch networks could be constructed using pairs of genes 
with double-negative feedback. The ON (upregulated)/OFF (downregulated) states could 
be used to model the transition [38-40]. It may be interesting to examine the recurrent 
positive feedback network motifs or functional modules during the sharp transitions. 
During evolution, gradually rewiring (i.e., adding new genomic aberrations and then 
recruiting new genes) of the clonal networks could gradually increase the power of 
positive feedback network motifs/modules until the threshold is reached, such that an 
extra event of genomic alteration will push a sharp transition to form a fast-growing 
clone. Early-warning signals (i.e., recurrent positive feedback network motifs/modules) 
could be dependent on the cell default state (e.g., cell of origin and germline variants), 
early genomic alteration events such as mutation of P53, Ras or EGFR, and the final key 
genomic alteration event which generates a fast-growing clone from its direct mother 
clone. In addition, early-warning signals could be represented by mutational signatures, 
which are indicative of genomic mutation patterns, or gene expression signatures, which 
represent gene expression changes during the transition. Some efforts have been made to 
look for early-warning signals of diseases, but experimental validations for these signals 
are still lacking [41].   
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In fact, we suspect that genome duplication event is most likely to be an early-warning 
signal (at least for breast cancer): (1) by analysis of 16 breast cancer cell lines, we found 
that cancer essential genes (i.e., knocking down such a gene will lead to cancer cell die or 
very slow-growing) have been enriched more than 50 times on average in amplified 
genes than driver-mutating genes; (2) from the breast cancer genome sequencing data 
generated by Nik-Zainal et al. [24] (Fig 1), we noted that most (10/15) of the tumor 
genomes experienced at least one genome duplication event which often leads to massive 
gene amplifications and deletions. Importantly, this event is often the last round of the 
gene amplification events and the late stage (fast-growing clones occur in late stage too) 
during tumor development. These data support our hypothesis that the accumulation of a 
certain number of amplified genes is critical for driving tumorigenesis. Based on these 
results, we suspected that genome duplication could be the rate-limiting step for tumor 
development, and therefore could be an early-warning signal for fast-growing clone 
formation. Network modules representing early-warning signals could be identified by 
differential network analysis of the networks which represent the clone before and after 
genome duplications. Furthermore, understanding of factors such as certain combinations 
of mutations or other environmental or epigenetic factors, which trigger genome 
duplication, could shed light on cancer prevention.   
 
3. Dissecting heterogeneity and modeling of drug resistance for personalized 
treatment   
Targeted cancer therapy is promising, however, in general only 20-30% of cancer 
patients respond to drug treatments in today’s clinical practice. The emergence of drug 
resistance in the course of treatment remains a major challenge in cancer therapy. 
Heterogeneity has been proposed as one of the major reasons for the failure of drug 
treatment in cancer management. Tumor genome sequencing suggests that a high degree 
of cancer cell heterogeneity exists in each tumor. Thus, one common source of drug 
resistance comes from the presence of multiple clones. Clinically, it is well-known that 
despite several different treatments, each somewhat successful at first, that tumors grow 
back again. It has been suggested that the drug kills one fast-growing clone (usually the 
dominant clone), but other fast-growing clones overtake it and the tumor reoccurs. By 
sequencing chronic lymphocytic leukemia (CLL) tumor genomes before and after 
chemotherapy, researchers found that patients whose original leukemia harbored clones 
with one or more cancer-driver genes often died sooner than patients without multiple 
clones [26]. Some fast-growing, but non-dominant, clones may have a fairly minimal 
presence before treatment and predominate after treatment. The clones that originally 
were somewhat rare or non-dominant may have gained a competitive advantage for 
proliferation and growth.  
To overcome heterogeneity-derived drug resistance, it is critical to dissect the clones and 
model their networks (clone-based networks) for cell survival (cancer hallmark-based 
networks). By modeling the cell survival networks of the fast-growing clones of a tumor, 
we could identify key genes as drug targets. It is unclear whether common drug targets 
exist for multiple fast-growing clones within a tumor. It is possible that the late-occurring 
fast-growing clones gain extra genomic alterations which could backup (i.e., redundant 
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functional pathways) the targets of its parental clones. It is necessary to model the backup 
within a clonal network, where a network component could functionally replace another 
one, especially in terms of cell survival and proliferation. For example, different gene 
alterations within the same pathway and cooperation of pathways perturbed by mutations 
can lead to the same phenotype. Finding the co-altered functional modules by integrating 
of mutations, CNVs and gene expressions could model network backup [42]. For 
generating a same phenotype, if Pathway A cooperates with Pathway B, and Pathway A 
cooperates with Pathway C, then Pathways B and C could be functionally backup each 
other. The synthetic lethality concept has been also explored for modeling of the 
functional redundancy within a network. For example, the synergistic outcome 
determination (SOD) approach, which constructs a synergistic network based on gene 
expression data and cancer prognostic information, has been used for performing module 
analysis to discriminate drugs from a broad set of test compounds and revealing the 
mechanisms of drug combinations [43]. The combinatorial perturbation approach, which 
constructs network models from perturbed molecular profiles assuming that after 
perturbation the system evolves according to nonlinear differential equations, has been 
used for identifying drug pairs to overcome network backup [44]. The current backup 
modeling approaches are still in their infancy, it is necessary to develop more advanced 
methods which could predict backup more accurately and more comprehensively.  
Current cancer treatments do not take clonal diversity into account and often target only 
the dominant fast-growing clone. Such an approach leaves the possibility that one of the 
minor fast-growing clones will then replicate and become dominant, leading to re-
occurrence of the tumor. Thus, modeling of the networks of both minor and dominant 
fast-growing clones within a tumor could provide a pivotal role in treating destructive 
cancers in the most efficient way. Many network methods for finding cancer genes or 
drug targets have been developed for a single network. One approach is modeling of 
networks by defining seed genes. These methods include predicting drug targets using 
metabolic networks [45], ranking genes based on PageRank concept (e.g., NetRank, [46], 
defining centrality measures according to their relevance to the seed genes in the network 
(e.g., NetworkPrioritizer, [47]), employing random walks (e.g., NetWalker, a context-
specific random walker [48]), or using a RVM-based ensemble model (TARGETgene, 
[49]). Another approach is performing an integrative analysis of mutations and CNVs on 
networks [50,51] or constructing causal-target networks using gene expression and 
CNV/mutations (e.g., using differentially expressed genes with CNVs to determine paths 
from causal alterations to these target genes based on network topology [52] or checking 
the mutations on the interaction interfaces between protein interactions [53]. Network 
perturbation has been explored to identify drug targets. For example, in silico 
perturbation of the receptors of the networks [54] or Boolean network perturbing of 
networks [55] have been used for finding drug targets. Karlebach and Shamir [56] used a 
network perturbation method to find the smallest perturbations on a network formulated 
as a Petri net which can yield a desired phenotype.  
Although many methods have been explored, there is still room for improving the 
accuracy of the predictions. By modeling clonal networks, it is possible to predict drug 
targets for each clone. If clones within a tumor do not share common targets, it would be 
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advantageous to identify multiple drug targets for individual. In this situation, 
combinatory therapy should be applied. Such an approach, which takes all the fast-
growing clones of a tumor into account, could help us tailor our therapy to those specific 
clones, and better predict which patients are likely to relapse. Moreover, it could help in 
developing novel therapeutic/patient-management paradigms that address the cancer 
evolutionary landscape and clonal diversity. 
Another common source of drug resistance comes from tumor microenvironments or 
stroma. Tumors are surrounded by multiple supportive cell types. Anticancer drugs that 
are capable of killing tumor cells are frequently rendered ineffective when the tumor cells 
are cultured in the presence of stromal cells. Straussman and colleagues [57] used a co-
culture system in which 45 cancer cell lines were cultured alone or with 1 of 23 stromal 
cell lines in the presence of 35 oncology drugs. They discovered that HGF, a ligand for 
the receptor tyrosine kinase (RTK) MET caused the resistance to a BRAF inhibitor 
(PLX4720). Validation experiments with HGF-neutralizing antibodies showed that HGF 
was both necessary and sufficient to confer drug resistance. They found stroma-mediated 
resistance was common in targeted agents. Overall, there was evidence of 
microenvironment-mediated resistance in up to 65% of the targeted agents studied. 
Similarly, Wilson and colleagues [58] showed that HGF attenuated the response of MET-
expressing melanoma cells to a BRAF inhibitor, and inhibition of MET blocked HGF-
induced resistance in vitro and in vivo. These findings suggest that stroma is an important 
source of anticancer drug resistance. Modeling of stromal-mediated resistance may 
provide a hitherto untapped strategy for overcoming drug resistance.  
Tumor-stromal communications mainly rely on signaling transduction mechanisms via 
ligand-receptor interactions, i.e., ligands secreted by stroma can activate receptor-
dependent pathways of tumor cells. Specific ligands secreted by stroma can promote drug 
resistance to a given drug. If we are able to predict the specific ligand-receptor 
interaction(s) that are likely to promote stroma-mediated resistance for a given drug, then 
we can predict which novel combinatorial therapy can be used for a tumor, i.e., which 
antibody will likely block stroma-mediated resistance and therefore sensitize the tumor to 
a specific drug. Clearly, modeling of the interactions between the signaling networks of 
fast-growing clones within a tumor and the stromal-signaling network could provide hints 
about resistance to the drugs that are used for treating each clone.  
As multiple clones co-exist in a tumor (Fig 2), they undoubtedly have relationships in 
terms of genetic profiles: (1) one clone could support the growth of other clones, for 
example, a clone could amplify a ligand such as FGF, which could trigger FGF signaling 
pathways in other clones;  or a clone could interact with the tumor microenvironment to 
protect itself and other clones within the tumor from host immune systems; (2) one clone 
could suppress another clone’s growth by either secreting inhibiting factors or  by using a 
larger portion of the available nutrients and growing aggressively to take over a large 
volume/space within a tumor; and (3) the clones grow independently and have no 
interactions with each other. Therefore, in addition to modeling clone-stroma network 
interactions, we also need to model clone-clone-stroma network interactions.  
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In summary, three levels of systems backups (i.e., functional redundancy) confer drug 
resistance: (1) new genomic alterations in late-occurring fast-growing clones could 
provide backup in network level so that a drug target in its parental clones could be not a 
target for the late-occurring fast-growing clones anymore; (2) the diversity of the fast-
growing clones within a tumor provides backup in the manner of ecological population 
dynamics; (3) interactions of clone-clone-stroma could provide backup at the host level. 
Better understanding of the backup at these levels should help develop new insights into 
how to tackle the problem of cancer. Ultimately, this will lead to new, more personalized 
treatments that will improve patient care. For example, tumor samples could be used for 
sequencing and “omic”-profiling, then data could be modeled using a systems approach, 
and finally combinatory drug targets will be proposed. The same tumor samples can be 
used to generate corresponding patient-derived mouse models for drug testing. By doing 
so, we could generate a ‘whole-system’ understanding of a tumor and provide a more 
efficient and personalized patient management strategy.    
 
4. Integrative network modeling  
 
One of the advantages of the systems approach is that multiple types of data could be 
integrated into one network and thus, integrative network modeling conducted. Although 
cancer has been recognized as a mutating disease, we cannot only focus on gene 
mutations. Almost all tumor genome sequencing papers have mainly discussed gene 
mutations. For example, they discussed which genes were highly mutated in samples, and 
even inferred major signaling pathways based purely on gene mutation information in the 
pathways [59-61]. These works often ignored many other factors such as CNVs, non-
coding RNAs and so on. For instance, more than 40% of the genes in each tumor genome 
have been either amplified or deleted, whereas less than 10% of the genes are 
functionally mutated. Given the fact that many more genes are affected by CNVs than by 
mutations, amplified or deleted genes could play more important roles than mutated 
genes in clonal evolution and tumorigenesis. Similarly, the number of alterations in non-
coding regions is proportionately higher than the number affecting coding regions. So are 
the numerous epigenetic changes in cancers. Integrative network modeling has been 
applied in cancer studies, for example, in constructing miRNA and post-translational 
networks [62-65], CNV-methylation-miRNA networks [66,67] or networks containing 
genes which are not only modulated but also mutated [68]. It is a worthy goal to transfer 
these analyses into clone-based networks and also consider emerging data types such as 
GWAS and single cell genome sequencing data. There are a growing number of massive 
international scientific collaborations such as Collaborative Oncological Gene-
environment Study (COGS) [69,70] for conducting GWAS studies. In addition, new 
single cell genome sequencing technologies are being developed. Single cell genome 
sequencing could help in generating high-quality data for clones, and even be applied to 
circulating tumor cells. By integrating all these diverse data, we could model cancer 
tumors more comprehensively and finally develop effectively management strategies for 
cancer patients.   
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Figure Legends 
 
Figure 1. Evolutionary timing of gene duplication events during tumorigenesis. The 
figure is modified from Nik-Zainal at al. [24]. Each line represents the timing of gene 
duplication events for each tumor. Most of the tumors have experienced genome 
duplication events, however, each tumor has experienced only one round of genome 
duplication, which is also the last gene duplication event.  
 
Figure 2. Interactions between clones and stroma. A tumor often contains several fast-
growing clones which could have interactions. The clones could also interact with stroma 
as well.  
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